Mental health · Alabama
Mental health studies in Alabama
29 studies have at least one recruiting site in Alabama. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
29 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Birmingham, AL + 50 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With…
LivaNova
- Location
- Birmingham, AL + 49 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Abbott Medical Devices
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 22–70
- RecruitingPhase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited
- Location
- Birmingham, AL + 27 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Saraland, AL + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 4
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
- Location
- Dothan, AL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Huntsville, AL + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Dothan, AL + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Birmingham, AL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Dothan, AL + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Huntsville, AL + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Huntsville, AL + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Huntsville, AL + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Huntsville, AL + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
- Location
- Dothan, AL + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
- Location
- Birmingham, AL + 31 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
University of Alabama at Birmingham
- Location
- Birmingham, AL + 1 other US site
- Eligibility basics
- Ages 10–24
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.